Sector News

Teva, Takeda add details on new venture in Japan

January 5, 2016
Life sciences

The independent company being created by a joint venture between Israel’s Teva Pharmaceutical Industries ($TEVA) and Japan’s Takeda Pharmaceutical became a bit more clear this week when the two pharma giants released additional details on their plans.

The companies said the products being shifted to the new company will include Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes. Sales revenue generated by those drugs totaled ¥125 billion ($1.03 billion) in fiscal 2014, which was 7% of Takeda’s total global revenue, according to a statement released by the two firms. The two also said the drug Leuplin will remain a part of Takeda in its oncology unit.

The companies said in the statement that Takeda’s overall revenue is expected to decline by ¥50 billion yen as a result of the deal.

Teva and Takeda said the new company, which will be majority owned by Teva, will be made up of Teva Takeda Pharma and Teva Takeda Yakuhin. The companies said the deal should be “EPS and cash flow accretive” in fiscal 2016 and that long-term growth in its generic business will also be positive.

Takeda’s hiving off of some of its no-growth drugs into the new company is an effort to focus on more financially rewarding new drugs, but the market for off-patent drugs and generics in Japan is expected to remain strong for the new company, because the country, like others in Asia, is trying to cut its national healthcare spending and rely more on such medicines.

By Matthew Driskill

Source: Fierce Pharma Asia

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.